NasdaqGM:TNGXBiotechs
Assessing Tango Therapeutics (TNGX) Valuation After Leadership Changes And New Pan RAS Supply Agreement
Event driven update on Tango Therapeutics
Tango Therapeutics (TNGX) has been in focus after appointing Malte Peters as CEO, shifting former CEO Barbara Weber to Executive Chair, signing a supply agreement with ERAS for pan RAS, and outlining upcoming pivotal trials.
See our latest analysis for Tango Therapeutics.
The stock has been volatile around these company updates, with a 1-day share price return of 8.25% and a 90-day share price return of 80.96%, while the 1-year total shareholder...